Table 1

Baseline characteristics among men receiving surgery or radiation therapy for curative intent and with complete data (N=623)

CharacteristicSurgery (N=225)
n (%)
Radiation (N=398)
n (%)
p Value*Both groups (N=623)
n (%)
Age (years)<0.001
 50–5919 (8.4)8 (2.0)27 (4.3)
 60–69143 (63.6)134 (33.7)277 (44.5)
 70–7963 (28.0)242 (60.8)305 (49.0)
 ≥800 (0)14 (3.5)14 (2.2)
Race/ethnicity0.83
 African-American25 (11.1)42 (10.6)67 (10.8)
 All other200 (88.9)356 (89.4)556 (89.2)
Comorbidity (Charlson score)<0.001
 0 (none)91 (40.4)103 (25.9)194 (31.1)
 1 (mild)70 (31.1)131 (32.9)201 (32.3)
 2 (moderate)47 (20.9)93 (23.4)140 (22.5)
 ≥3 (severe)17 (7.6)71 (17.8)88 (14.1)
Anatomic stage0.04
 Localized (T1, T2)221 (98.2)374 (94.0)595 (95.5)
 Regional (≥T3)4 (1.8)24 (6.0)28 (4.5)
Differentiation (Gleason score)0.046
 Well (2–4)57 (25.3)81 (20.4)138 (22.2)
 Moderate (5–7)147 (65.3)254 (63.8)401 (64.4)
 Poor (8–10)21 (9.4)63 (15.8)84 (13.5)
Baseline PSA† (ng/mL)<0.001
 0 to <4.039 (17.3)38 (9.5)77 (12.4)
 4.0 to <10.0105 (46.7)157 (39.5)262 (42.1)
 10.0 to <20.049 (21.8)118 (29.6)167 (26.8)
 ≥20.029 (12.9)84 (21.1)113 (18.1)
 Unknown3 (1.3)1 (0.3)4 (0.6)
  • *p Value is for the χ2 test comparing patients receiving surgery versus radiation therapy.

  • †Of note, each patient had an average of 8.2 PSA tests done from zero-time to failure.

  • PSA, prostate-specific antigen.